Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.75 |
| ▸ | WEE1 | P30291 | 5/20 | 0.75 |
| ▸ | EGFR | P00533 | 4/20 | 0.72 |
| ▸ | ABL1 | P00519 | 4/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.72 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.72 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | PAK4 | O96013 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108141 | 0.95 | FGFR1 (0.91) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL10108489 | 0.94 | FGFR1 (0.89) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL2246976 | 0.90 | FGFR1 (0.82) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL10102543 | 0.88 | FGFR1 (0.86) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL2083345 | 0.87 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL25400558 | 0.86 | FGFR1 (0.76) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL30618277 | 0.86 | FGFR1 (0.76) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL1335649 | 0.86 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL29750113 | 0.86 | FGFR1 (0.78) | FGFR1SRCPDGFRBPDGFRAWEE1 | |
| SCHEMBL6642569 | 0.85 | FGFR1 (0.88) | FGFR1SRCWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | FGFR1 115/4885SRC 176/4885PDGFRB 694/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | FGFR1 136/4885SRC 194/4885PDGFRB 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.